0000075252false00000752522026-11-162026-11-16

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 16, 2026

Accendra Health, Inc.

(Exact name of registrant as specified in its charter)

​

​

​

​

​

​

Virginia

001-09810

54-1701843

(State or other jurisdiction of

(Commission

(I.R.S. Employer

incorporation or organization)

File Number)

Identification No.)

​

​

​

4435 Waterfront Drive, Suite 300,

Glen Allen, Virginia

​

23060

(Address of principal executive

​

​

offices)

​

(Zip Code)

​

​

​

​

Registrant’s telephone number, including area code (804) 277-4304

Securities registered pursuant to Section 12(b) of the Act:

​

​

​

​

​

​

Title of each class

  ​ ​ ​

Trading Symbol(s)

  ​ ​ ​

Name of each exchange on which registered

Common Stock, $2 par value per share

​

ACH

​

New York Stock Exchange

​

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.below):

​

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

​

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

​

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

​

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company         ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.          ◻

​

​

​

Item 3.01Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On November 16, 2026, Accendra Health, Inc. (the “Company”) received notice (the “Notice”) from the New York Stock Exchange (“NYSE”) Regulation that it has suspended trading of the Company’s common stock and determined to commence proceedings to delist the Company’s common stock from the NYSE. The NYSE Regulation determined that the Company’s common stock is no longer suitable for listing based on abnormally low selling price levels, pursuant to Section 802.01D of the NYSE Listed Company Manual.

​

The Company has a right to a review of this determination by a Committee of the Board of Directors of the Exchange. The Notice states that it will apply to the U.S. Securities and Exchange Commission to delist the Company’s common stock pending completion of applicable procedures, including any appeal by the Company of its determination. The Company does not intend to appeal the NYSE’s determination. 

​

The Company’s common stock began trading on the OTCQB market under the ticker symbol “ACCH” on November 17, 2026.

​

Item 7.01.Regulation FD Disclosure.

On November 17, 2026, the Company issued a press release regarding the delisting determination. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

​

The information in Exhibit 99.1 is being furnished pursuant to Item 7.01 of Form 8-K. In accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.

​

Item 9.01.

Financial Statements and Exhibits.

​

(d) Exhibits.

The following materials are filed as exhibits to this Current Report on Form 8-K.

 

Exhibit Number 

 

Description

99.1

​

Press Release of the Company, dated November 17, 2026 (furnished pursuant to Item 7.01).

104

 

Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document).

​

​

​

​

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

​

​

​

​

​

​

​
ACCENDRA HEALTH, INC.

​

​

​

November 17, 2026

​

/s/ Jonathan A. Leon

​

​

 ​

Jonathan A. Leon

​

​

​

Executive Vice President and Chief Financial Officer

​


ATTACHMENTS / EXHIBITS

ATTACHMENTS / EXHIBITS

EX-99.1

EX-101.SCH

EX-101.DEF

EX-101.LAB

EX-101.PRE

IDEA: R1.htm

IDEA: FilingSummary.xml

IDEA: MetaLinks.json

IDEA: ach-20261116x8k_htm.xml